Table 2.
Comparison of disease severity among patients with MIS‐C from the OC‐19 and BATS cohorts
| OC‐19 patients (n = 349) | BATS patients who meet the WHO case definition (n = 350) | ||||
|---|---|---|---|---|---|
| Data available, n (%) | Result, n (%) or median (IQR) | Data available, n (%) | Result, n (%) or median (IQR) | P | |
| Admission to an intensive care unit a | 349 (100.0) | 213 (61.0) | 346 (98.9) | 155 (44.8) | <0.001 |
| Receipt of vasopressors or inotropes a | 349 (100.0) | 138 (39.5) | 349 (100.0) | 80 (22.9) | <0.001 |
| Invasive mechanical ventilation a | 349 (100.0) | 20 (5.7) | 350 (100.0) | 23 (6.6) | 0.75 |
| Extracorporeal membrane oxygenation a | 349 (100.0) | 4 (1.1) | 350 (100.0) | 1 (0.3) | 0.22 |
| Hospital death | 349 (100.0) | 0 (0.0) | 331 (94.6) | 6 (1.8) | 0.01 |
| CRP a (mg/dl) | 289 (82.8) | 15.4 (7.9‐23.4) | 340 (97.1) | 15.2 (9.3‐22.5) | 0.64 |
| Ferritin a (ng/ml) | 225 (64.5) | 390 (220‐822) | 301 (86.0) | 444 (245‐774) | 0.40 |
| Troponin a , b (ng/ml) | 172 (49.3) | 0.11 (0.02‐0.57) | 252 (72.0) | 0.04 (0.01‐0.15) | ND |
| BNP a , b (pg/ml) | 132 (37.8) | 405 (79‐1071) | 100 (28.6) | 127 (43‐583) | ND |
| NT‐proBNP a , b (pg/ml) | 87 (24.9) | 1106 (221‐2645) | 138 (39.4) | 1860 (468‐8137) | ND |
Abbreviations: BATS, Best Available Treatment Study; BNP, brain natriuretic peptide; CRP, C‐reactive protein; IQR, interquartile range; MIS‐C, multisystem inflammatory syndrome in children; ND, not done; NT‐proBNP, N‐terminal pro–brain natriuretic peptide; OC‐19, Overcoming COVID‐19 Public Health Surveillance Registry; WHO, World Health Organization.
a
Pretreatment.
b
P values not calculated for biomarkers measured in <50% of patients in either cohort.